In addition to PD-L1 and TMB, there are several other parameters associated with immune checkpoint inhibitor outcomes, such as prognostic scores like LIPI and dNLR, tumour-infiltrating lymphocytes (TILs), T-effector/IFN-γ signatures, general immune fitness, soluble inhibitors, tumour metabolism, and the microbiome. Here, IFNG is linked to neoplasm.